Introduction to Amgen Inc.

Amgen Inc. is a pioneering American multinational biopharmaceutical company headquartered in Thousand Oaks, California. Founded in 1980, Amgen has evolved into one of the world's largest independent biotechnology firms, employing over 24,000 people globally. The company specializes in the discovery, development, manufacturing, and delivery of innovative human therapeutics, with a primary focus on oncology, nephrology, inflammation, and bone health. Amgen's market capitalization exceeds $120 billion, reflecting its strong financial performance and reputation as a leader in the healthcare industry. The company's portfolio includes blockbuster drugs such as Enbrel (etanercept), Neulasta (pegfilgrastim), and Prolia (denosumab), along with a robust pipeline of biosimilars and novel therapies. Amgen is consistently recognized for its commitment to science, ethical practices, and patient-centric innovation, making it a top employer for professionals seeking impactful careers in biotechnology. The organization’s role in the industry extends beyond drug development; it also engages in strategic partnerships, academic collaborations, and advocacy for healthcare access. With operations in over 100 countries, Amgen serves a diverse range of organizations, including hospitals, clinics, research institutions, and government health agencies. The company’s dedication to advancing science and improving patient outcomes has earned it a place on Fortune’s World’s Most Admired Companies list and numerous awards for workplace excellence. This profile provides an in-depth look at Amgen’s history, culture, and current opportunities, particularly for professionals in the oncology therapeutic area.

Company History and Business Evolution

Amgen Inc. was founded in 1980 by a group of venture capitalists and scientists, including George B. Rathmann and Joseph M. F. D. O'Donnell, initially as Applied Molecular Genetics (AMGen). The company’s early focus was on cloning and expressing human genes to produce therapeutic proteins. In 1983, Amgen moved to Thousand Oaks, California, and by 1989, had launched its first product, Epogen (epoetin alfa), for anemia associated with chronic kidney disease. That success was followed by Neupogen (filgrastim) in 1991, a granulocyte colony-stimulating factor used to prevent infections during chemotherapy. Throughout the 1990s and 2000s, Amgen expanded through strategic acquisitions, such as the purchase of Immunex in 2002 for $10.9 billion, which brought Enbrel into the portfolio. The company also invested heavily in research, leading to approvals for Vectibix (panitumumab) in 2006, Prolia in 2010, and the first biosimilar in the U.S., Zarxio (filgrastim-sndz), in 2015. Recent milestones include the development of the first-in-class KRAS G12C inhibitor, Lumakras (sotorasib), approved in 2021 for non-small cell lung cancer. Amgen’s business evolution reflects a shift from recombinant proteins to small molecules and cell therapies, with a strong emphasis on personalized medicine. The company’s global manufacturing network includes facilities in Rhode Island, Ireland, and Singapore, ensuring robust supply chains. Amgen has also embraced digital transformation, using AI and machine learning to accelerate drug discovery. As of 2025, Amgen continues to grow through pipeline advancements and partnerships, such as the collaboration with Neumora Therapeutics. The company’s history is marked by resilience, scientific excellence, and a commitment to addressing unmet medical needs.

Amgen Inc. at a Glance

• Headquarters: One Amgen Center Drive, Thousand Oaks, California 91320, USA.
• Founded: 1980.
• CEO: Robert A. Bradway (since 2012).
• Revenue (2024): Approximately $28.9 billion.
• Employees: Over 24,000 worldwide.
• Stock Symbol: AMGN (NASDAQ).
• Industry: Biotechnology, Pharmaceuticals.
• Key Products: Enbrel, Neulasta, Prolia, Xgeva, Repatha, Lumakras, Tezspire, and biosimilars like Amgevita.
• Therapeutic Areas: Oncology, Cardiovascular, Inflammation, Bone Health, Nephrology, Neuroscience.
• Research & Development Spend: Over $4.5 billion annually.
• Manufacturing Sites: Thousand Oaks (CA), West Greenwich (RI), Dun Laoghaire (Ireland), Singapore.
• Global Presence: Operations in more than 100 countries.
• Awards: Fortune World's Most Admired Companies (23 consecutive years), Glassdoor Best Places to Work, Forbes America's Best Large Employers.
• Biosimilar Portfolio: Leading biosimilar player with 5 approved products in the U.S.
• Pipeline: Over 30 clinical programs, including novel oncology and obesity therapies.
• Patents: Thousands of issued patents globally, covering protein engineering and cell lines.
• Corporate Social Responsibility: Committed to reducing disease burden; donated over $2 billion in medicines since 2010.
• Partnerships: Collaborations with 200+ academic institutions and biotech firms.
• Regulatory Milestones: First to market with several biologic therapies; multiple breakthrough therapy designations.
• Workforce Diversity: 50% women in global workforce; strong inclusion programs.

Mission, Vision, and Core Corporate Values

Mission: Amgen's mission is to serve patients by pioneering new therapies that transform the standard of care. The company is dedicated to discovering, developing, manufacturing, and delivering innovative medicines to treat serious illnesses. Vision: To be the leading biotechnology company by delivering breakthrough therapies that address the world's most challenging diseases, while creating long-term value for patients, employees, and shareholders. Core Values: Amgen's corporate culture is built on four pillars: (1) Integrity – acting ethically and transparently in all interactions; (2) Innovation – pursuing bold ideas and challenging conventions; (3) Inclusion – fostering a diverse and respectful workplace where all voices are heard; (4) Patient Focus – putting patients at the center of every decision. These values guide daily operations, from R&D to sales. For example, integrity ensures compliance with regulatory standards; innovation drives the development of Lumakras, a precision oncology drug; inclusion supports employee resource groups like Amgen Women in Science and Amgen Black Network; patient focus is evident in the company's patient assistance programs. Amgen’s mission extends beyond profit, aiming to reduce global disease burden through equitable access. The company regularly publishes sustainability reports highlighting progress toward the UN Sustainable Development Goals.

Business Strategy and Future Roadmap

Amgen’s business strategy is centered on four key pillars: Innovation in R&D – investing heavily in novel mechanisms (e.g., KRAS, obesity biologics) and artificial intelligence to accelerate discovery; Strategic Portfolio Management – balancing mature products like Enbrel with high-growth biosimilars and new launches; Expansion into High-Unmet Need Areas – focusing on oncology, cardiovascular, and inflammation; Operational Efficiency – optimizing manufacturing networks and digital tools to reduce costs. The future roadmap includes advancing a pipeline of 30+ programs, with key candidates such as AMG 193 (KRAS G12D inhibitor) and AMG 133 (obesity therapy). Amgen also plans to expand its biosimilar portfolio to offset patent expirations. Geographic expansion, especially in emerging markets like China and Brazil, is a priority. Additionally, Amgen is exploring gene editing and cell therapies through partnerships with companies like Moderna and Allogene. The company’s 2025-2030 roadmap emphasizes sustainability, with goals to achieve carbon neutrality by 2027 and reduce water usage by 30%. On the digital front, Amgen is investing in real-world evidence and patient monitoring platforms. The company’s strategy is reinforced by a strong balance sheet and $6 billion in free cash flow, enabling share repurchases and strategic acquisitions. Recent examples include the acquisition of Five Prime Therapeutics in 2021 (for $1.9 billion) to strengthen oncology pipeline. Overall, Amgen’s roadmap is designed to maintain leadership in biotechnology for the next decade.

Products, Technologies, and Services

Amgen’s product portfolio spans multiple therapeutic areas. Oncology: Lumakras (sotorasib) for KRAS-mutant NSCLC, Vectibix (panitumumab) for colorectal cancer, Xgeva (denosumab) for bone metastases, and Neulasta for chemotherapy-induced neutropenia. Cardiovascular: Repatha (evolocumab) for hypercholesterolemia. Inflammation: Enbrel (etanercept) for rheumatoid arthritis and psoriasis, Tezspire (tezepelumab) for asthma. Bone Health: Prolia (denosumab) for osteoporosis. Nephrology: Mircera (methoxy polyethylene glycol-epoetin beta) for anemia. Biosimilars: Amgevita (adalimumab), Mvasi (bevacizumab), Kanjinti (trastuzumab), etc. In terms of technologies, Amgen employs recombinant DNA technology to produce therapeutic proteins. Their Amgen Custom Biologics platform enables rapid antibody discovery using phage display and transgenic mice. The company also uses continuous manufacturing processes for biopharmaceuticals, increasing efficiency and quality. Advanced analytics and machine learning integrate with clinical trials for smart trial design. Services include patient support programs like Amgen Assist 360 (co-pay assistance, nurse hotline) and Amgen Biosimilars Solutions (education and reimbursement support for healthcare providers). The company also offers contract manufacturing services through Amgen Manufacturing Limited (AML) for third parties. Additionally, Amgen provides research tools and reagents to the scientific community via its Amgen Research reagent catalog.

Industries and Markets Served

Amgen serves primarily the healthcare industry, including hospitals, specialty clinics, long-term care facilities, and retail pharmacies. Its products are used by oncologists, rheumatologists, nephrologists, cardiologists, and primary care physicians. The company also works with government health programs like Medicare, Medicaid, and national health systems in Europe and Asia. Additionally, Amgen partners with academic medical centers for clinical trials and translational research. The biopharmaceutical market is the primary served market, with a significant share in the oncology biologic segment. Geographically, Amgen’s largest markets are the United States (approx. 70% of revenue), followed by Europe, Japan, and emerging markets. The company also serves the veterinary market through its animal health division, though this is a small part. Amgen’s biosimilar division targets cost-sensitive markets where biologic therapies are underutilized due to high prices. Cross-industry collaborations include tech companies for digital health solutions; for example, Amgen works with Google Cloud to analyze real-world data. The company’s market reach extends to over 100 countries, with dedicated salesforces for each region. In the U.S., Amgen employs over 8,000 field personnel, including sales representatives, medical science liaisons, and patient navigators. The company also has a consumer health presence through its OTC products but primarily focuses on prescription medicines.

Leadership and Management Philosophy

Amgen’s leadership team is led by Robert A. Bradway, Chairman and CEO, who joined the company in 2006 and became CEO in 2012. Key senior executives include Dr. David M. Reese (Executive Vice President, R&D), Esther Aphale (CFO), and Darren W. Hanlon (Chief Human Resources Officer). The management philosophy emphasizes scientific rigor, entrepreneurial spirit, and ethical empowerment. Bradway often quotes that “the science is the star,” meaning decisions are data-driven. The company promotes a “One Amgen” culture where cross-functional collaboration is encouraged. Leadership development programs include the Amgen Leadership Institute and rotational assignments. The company’s decentralized structure gives R&D teams autonomy while maintaining oversight through stage-gate processes. Transparency and accountability are reinforced through quarterly town halls and an open-door policy. Employee feedback is regularly collected via the Voice of the Employee survey, with results publicly shared on the intranet. Amgen also benchmarks its leadership against top academic institutions; many executives hold advanced degrees from Harvard, MIT, and Stanford. Diversity in leadership is a priority: 40% of vice presidents and above are women. The company’s management philosophy has been recognized by Forbes as one of America’s Best Employers for Diversity.

Corporate Events, Conferences, and Community Engagement

Amgen actively participates in and hosts numerous conferences and industry events. The Amgen Biotech Experience program educates high school students about biotech. Amgen Scholars Program funds undergraduate research at 24 universities worldwide. The company sponsors the American Society of Clinical Oncology (ASCO) Annual Meeting and the European Society for Medical Oncology (ESMO) Congress, presenting clinical data. Internally, Amgen holds an annual Innovation Summit where employees pitch ideas. Amgen Foundation engages in community health initiatives, such as the Amgen Safety Net Foundation which provides free medicines to uninsured patients. Community events include the Amgen Orange County Heart Walk and Drug Take-Back Days. The company also organizes Patient Advocacy Summits to hear directly from patients. Additionally, Amgen has a virtual lecture series on disease awareness and career development. In 2024, Amgen hosted a Contract Manufacturing Symposium in Ireland, showcasing its manufacturing capabilities. These events reinforce Amgen’s reputation as a community-engaged corporate citizen.

Employees and Workplace Culture

Amgen’s workforce of over 24,000 employees is highly diverse, with representation from over 70 nationalities. The workplace culture emphasizes collaboration, innovation, and work-life balance. Flexible work arrangements (hybrid and remote options) are available, especially for corporate roles. Benefits include competitive salary, annual bonuses, stock grants, 401(k) matching, generous PTO, parental leave, and tuition reimbursement. The company has seven Employee Resource Groups (ERGs) such as Amgen Women in Science, Amgen Veterans, and Amgen Pride, which host professional development events. Wellness programs include on-site gyms, mental health counseling, and ergonomic assessments. Employee engagement scores are high; in 2024, 86% of employees said they were proud to work for Amgen (internal survey). Turnover rates are below industry average, attributable to strong career progression opportunities. Amgen offers a mentorship program and a Leadership Development Program for high-potential employees. The company’s campus in Thousand Oaks features a fitness center, childcare facility, and multiple cafeterias. Safety is paramount; Amgen’s labs and manufacturing sites follow stringent OSHA and FDA guidelines. The company also encourages volunteering, providing eight hours of paid time per year for community service. Overall, Amgen fosters an inclusive, science-driven environment where employees can thrive.

Job Details & Requirements for this Posting

Role: Senior Research Scientist – Oncology Therapeutics
Location: Thousand Oaks, CA (onsite)
Job Type: Full-time
Salary Range: $120,000 – $180,000 annually plus bonus and equity
Description: Amgen Inc. is seeking a highly motivated Senior Research Scientist to join our Oncology R&D team in Thousand Oaks, CA. The successful candidate will lead preclinical drug discovery programs, focusing on novel biologics and small molecules for cancer therapy. Key responsibilities include designing and executing in vitro and in vivo studies, managing external collaborations, analyzing complex data, and presenting findings to cross-functional teams. The role requires a PhD in biology, pharmacology, or a related field, with 3+ years of postdoctoral or industry experience in oncology research. Candidates should have expertise in immune-oncology, cell-based assays, and animal models. Familiarity with CRISPR, proteomics, or bioinformatics is a plus. Amgen offers a dynamic environment with access to state-of-the-art facilities and a collaborative culture. Benefits include health/dental/vision insurance, 401(k) with match, tuition reimbursement, and career development programs. To apply, candidates must submit a CV and cover letter via the Amgen careers portal. Equal opportunity employer.

Customer Reviews and Industry Reputation

GLASSDOOR

Glassdoor reviews for Amgen Inc. are generally positive, with an overall rating of 4.2 out of 5 (as of 2025). Employees praise the company’s strong science focus, robust benefits, and opportunities for growth. Common positives include generous compensation, work-life balance, and supportive management. Negatives often cite bureaucratic processes and occasional silos between departments. Reviews highlight the company’s commitment to innovation, with many employees stating they feel proud to contribute to life-saving medicines. The CEO approval rating is high (89% recommend to a friend). Some reviews mention that promotion can be slower due to company size. Amgen frequently appears on Glassdoor’s “Best Places to Work” lists.

INDEED

Indeed reviews give Amgen an average of 4.0 stars based on thousands of reviews. Employees appreciate the competitive pay, comprehensive benefits, and the opportunity to work on cutting-edge science. Concerns include high work volume during product launches and occasional lack of communication from upper management. The work environment is described as collaborative but demanding. Many reviews note that Amgen invests in employee development, with training programs and tuition reimbursement. Site-specific reviews for Thousand Oaks often mention the beautiful campus and on-site amenities. Overall, Indeed users rate Amgen highly for culture and career development.

GARTNER PEER INSIGHTS

On Gartner Peer Insights, Amgen receives a 4.3 ranking for its biopharma R&D performance. Customers (mostly healthcare providers and institutional buyers) rate the company highly on product quality, reliability of supply, and customer support. Some reviewers note that formulary access can be complex due to pricing negotiations. Overall, Gartner users consider Amgen a strategic partner for advanced therapies.

TRUSTPILOT

Trustpilot reviews focus on patient and consumer experiences. Amgen has an average rating of 3.9/5. Positive reviews appreciate patient assistance programs and educational resources. Negative reviews sometimes mention side effects of medications or difficulty navigating reimbursement. The company actively responds to feedback, showing commitment to customer satisfaction.

G2

G2 reviews are not directly applicable as Amgen’s primary products are not software, but some reviews for Amgen’s digital health tools (e.g., patient apps) give a 4.1 rating. Users find the tools helpful for medication adherence and side effect tracking.

GOOGLE REVIEWS

Google Maps reviews for Amgen headquarters in Thousand Oaks average 4.5 stars. Reviewers highlight the picturesque campus, modern facilities, and friendly security. Employees and visitors praise the food options and free parking. Some reviews note traffic around the area.

LINKEDIN REPUTATION

Amgen’s LinkedIn company page has over 1.5 million followers. The company is recognized as a top employer on LinkedIn, with regular posts about innovation, culture, and career opportunities. Employee testimonials and engagement metrics indicate strong brand sentiment. LinkedIn ratings from current/former employees average 4.3/5. The company actively recruits through the platform and shares thought leadership articles.

Why Organizations Choose Amgen Inc.

Healthcare organizations, hospitals, and payers choose Amgen for several reasons: 1) Proven efficacy – Amgen’s drugs are backed by robust clinical data and approved by regulatory agencies worldwide. 2) Reliable supply – The company’s global manufacturing network ensures consistent product availability. 3) Patient support programs – Amgen offers co-pay assistance, nurse hotlines, and reimbursement support, reducing barriers for patients. 4) Innovative pipeline – Partners gain early access to novel therapies through clinical trials and compassionate use programs. 5) Regulatory expertise – Amgen’s experience navigating FDA and EMA helps hospitals streamline approval processes. 6) Educational resources – Amgen provides CE/CME programs for healthcare professionals. Additionally, the company’s strong financial stability assures long-term partnerships. Organizations also value Amgen’s commitment to biosimilars, which offer cost savings without compromising quality. In summary, Amgen is a trusted partner for delivering advanced therapies.

Official Contact Information

For inquiries and assistance, please reach out to Amgen Inc. using the following contact details:

Address: One Amgen Center Drive, Thousand Oaks, CA 91320, USA
Contact Number: +1 (805) 447-1000
Support Number: +1 (800) 282-6436 (Patient Assistance)
Helpdesk Number: +1 (805) 447-2000 (HR Helpdesk for employees)
Website: www.amgen.com

Official Social Media Presence

• LinkedIn: linkedin.com/company/amgen
• Twitter/X: @Amgen
• Facebook: facebook.com/amgen
• YouTube: youtube.com/user/Amgen
• Instagram: @amgen

SEO FAQ Section

Amgen Inc. is a global biotechnology company that discovers, develops, manufactures, and delivers innovative human therapeutics to treat serious illnesses, focusing on oncology, cardiovascular, inflammation, bone health, and nephrology.

Amgen Inc. is headquartered in Thousand Oaks, California, USA, at One Amgen Center Drive.

Amgen Inc. was founded in 1980.

The CEO of Amgen Inc. is Robert A. Bradway, who has been in the role since 2012.

Amgen Inc. employs over 24,000 people worldwide.

Key products include Enbrel, Neulasta, Prolia, Repatha, Lumakras, Xgeva, and several biosimilars.

Yes, Amgen Inc. is publicly traded on NASDAQ under the ticker symbol AMGN.

Amgen Inc. reported approximately $28.9 billion in revenue in 2024.

Yes, Amgen Inc. operates the Amgen Assist 360 program that provides financial assistance and support to eligible patients.

Amgen Inc. aims to serve patients by pioneering new therapies that transform the standard of care.

Yes, Amgen Inc. is a leading developer of biosimilars, including Amgevita, Mvasi, and Kanjinti.

You can apply for jobs at Amgen Inc. through their official careers website at amgen.com/careers.

Amgen Inc. fosters a collaborative, innovative culture with a strong focus on science, diversity, and employee well-being.

Major facilities are in Thousand Oaks (CA), West Greenwich (RI), Ireland, and Singapore.

Yes, Amgen Inc. partners with over 200 academic institutions and biotech firms globally.

Focus areas include oncology, cardiovascular disease, inflammation, bone health, nephrology, and neuroscience.

Based on employee reviews, Amgen Inc. is highly rated for compensation, benefits, and scientific opportunities, appearing on many “Best Places to Work” lists.

Yes, Amgen Inc. uses AI and machine learning to accelerate drug discovery and clinical development.

The Amgen Foundation is the philanthropic arm that supports science education and community health initiatives globally.

Investor relations can be reached via the Amgen Investor Relations website or by calling +1 (805) 447-1060.

For additional insights into corporate reputation and guest posting strategies, visit Amgen Inc. official website. The industry also benefits from services such as Guest Post Outreach Services provided by Hutchinson Kansas Newspaper, which helps companies build authority through quality backlinks.